Q: What is Renflexis used for?

Renflexis is used to treat the following conditions: Crohn's disease Ulcerative colitis Rheumatoid arthritis Others

Q: How does Renflexis work?

Mechanism of Action Renflexis belongs to a class of medications known as tumor necrosis factor (TNF) blockers. It works by targeting and binding to a protein called TNF-alpha, which is produced by the body's immune system. In a healthy body, TNF-alpha helps regulate the immune response. However, in people with certain autoimmune conditions, the body produces excessive amounts of this protein. High levels of TNF-alpha lead to inflammation, which can cause pain, swelling, and damage to various parts of the body, such as the joints, skin, or digestive tract. By binding to TNF-alpha, Renflexis prevents the protein from interacting with healthy cells. This action helps to: Reduce the inflammatory response. Decrease symptoms associated with autoimmune disorders. Help prevent further damage to tissues and organs. Induce and maintain remission in certain chronic conditions. As a biosimilar, Renflexis is designed to be highly similar to its reference product, Remicade, and works through the same biological pathways to manage inflammation.

Q: What are the active ingredients in Renflexis?

The active ingredient in Renflexis is infliximab .

Q: What are the side effects of Renflexis?

Common side effects of Renflexis may include: upper respiratory tract infection headache infusion reactions Always consult with a healthcare professional about potential side effects.

Q: What drug class is Renflexis?

Renflexis belongs to the TNF inhibitor drug class.

Q: What is the dosage of Renflexis and how do I take it?

Administration Method Renflexis is administered as an intravenous (IV) infusion, which means it is delivered directly into a vein. This procedure is performed by a healthcare professional in a medical setting, such as a clinic or hospital. The infusion process requires a period of time to complete. Dosing Pattern The treatment usually begins with a series of initial doses to establish the medication in your system. After these starting doses, you will transition to a maintenance schedule where infusions are given at regular intervals. Your healthcare provider will determine the specific timing based on your medical condition and how you respond to the therapy. Observation Period During and after the infusion, medical staff will monitor you for any immediate reactions to the medication. It is important to stay for the entire observation period as directed by your healthcare team. Missed Appointments For the treatment to be effective, it is important to follow the scheduled timeline. If you are unable to attend an infusion appointment, notify your healthcare provider immediately to arrange a new time for your dose.

Q: Is Renflexis safe during pregnancy and breastfeeding?

Pregnancy Research regarding the use of Renflexis during pregnancy is limited. As a monoclonal antibody, Renflexis can cross the placenta, especially during the third trimester. This may lead to the medication being present in the newborn's system at birth, which could potentially affect the infant's immune response. If Renflexis is used during pregnancy, it is important for the healthcare team to be aware. Infants exposed to the drug in utero may need a modified vaccination schedule. Specifically, live vaccines are generally not recommended for these infants for at least six months after birth due to the potential risk of infection. Breastfeeding Infliximab products have been detected in human breast milk at low concentrations. While the medication is likely broken down in the infant's digestive tract, which may limit systemic absorption, the full impact on a nursing child is not completely understood. Individuals who are breastfeeding or planning to breastfeed should consult with their doctor to evaluate the necessity of the treatment and any potential risks to the infant.

Q: What forms and strengths does Renflexis come in?

Renflexis is supplied in the following form: Lyophilized powder for injection: This is a sterile, white, preservative-free powder provided in a single-dose vial. This medication is not for self-administration. A healthcare provider must reconstitute the powder with a liquid and then further dilute it before it is administered. The final solution is given through a needle into a vein, which is called an intravenous (IV) infusion.

Q: What is the FDA approval status of Renflexis?

FDA Approval and Indications Renflexis (infliximab-abda) was approved by the FDA in 2017 as a biosimilar to Remicade. It is approved for the treatment of several chronic inflammatory conditions in adults and, in some cases, children. These include: Crohn’s disease (adults and children 6 years and older) Ulcerative colitis (adults and children 6 years and older) Rheumatoid arthritis (in combination with methotrexate) Ankylosing spondylitis Psoriatic arthritis Plaque psoriasis Boxed Warning The FDA requires a boxed warning for Renflexis due to the risk of serious infections and malignancy. Patients treated with this medication are at increased risk for developing serious infections that may lead to hospitalization or death, including tuberculosis (TB), bacterial sepsis, and invasive fungal infections. Patients should be tested for latent TB before starting treatment and monitored during therapy. Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers. Specifically, cases of hepatosplenic T-cell lymphoma have occurred, primarily in adolescent and young adult males with inflammatory bowel disease treated with these products and other immunosuppressants. Regulatory Classification As a biosimilar, Renflexis is highly similar to its reference product, Remicade, with no clinically meaningful differences in safety, purity, or potency. It is administered via intravenous infusion by a healthcare professional in a clinical setting.

Question 1

What is Renflexis?

Accepted Answer

Renflexis is a monoclonal antibody that works by binding to and neutralizing tumor necrosis factor-alpha (TNF-alpha), a substance in the body that causes inflammation. By blocking this protein, the medication helps to decrease the inflammatory response associated with certain chronic conditions.

This medication is classified as a biosimilar, which means it is highly similar to an existing biological medicine already approved for use. It functions as a tumor necrosis factor (TNF) blocker to help manage systemic inflammation.

Question 2

What is Renflexis used for?

Accepted Answer

Renflexis is used to treat the following conditions:

Crohn's disease
Ulcerative colitis
Rheumatoid arthritis
Others

Question 3

How does Renflexis work?

Accepted Answer

Mechanism of Action

Renflexis belongs to a class of medications known as tumor necrosis factor (TNF) blockers. It works by targeting and binding to a protein called TNF-alpha, which is produced by the body's immune system.

In a healthy body, TNF-alpha helps regulate the immune response. However, in people with certain autoimmune conditions, the body produces excessive amounts of this protein. High levels of TNF-alpha lead to inflammation, which can cause pain, swelling, and damage to various parts of the body, such as the joints, skin, or digestive tract.

By binding to TNF-alpha, Renflexis prevents the protein from interacting with healthy cells. This action helps to:

Reduce the inflammatory response.
Decrease symptoms associated with autoimmune disorders.
Help prevent further damage to tissues and organs.
Induce and maintain remission in certain chronic conditions.

As a biosimilar, Renflexis is designed to be highly similar to its reference product, Remicade, and works through the same biological pathways to manage inflammation.

Question 4

What are the active ingredients in Renflexis?

Accepted Answer

The active ingredient in Renflexis is infliximab.

Question 5

What are the side effects of Renflexis?

Accepted Answer

Common side effects of Renflexis may include:

upper respiratory tract infection
headache
infusion reactions

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Renflexis?

Accepted Answer

Renflexis belongs to the TNF inhibitor drug class.

Question 7

What is the dosage of Renflexis and how do I take it?

Accepted Answer

Administration Method

Renflexis is administered as an intravenous (IV) infusion, which means it is delivered directly into a vein. This procedure is performed by a healthcare professional in a medical setting, such as a clinic or hospital. The infusion process requires a period of time to complete.

Dosing Pattern

The treatment usually begins with a series of initial doses to establish the medication in your system. After these starting doses, you will transition to a maintenance schedule where infusions are given at regular intervals. Your healthcare provider will determine the specific timing based on your medical condition and how you respond to the therapy.

Observation Period

During and after the infusion, medical staff will monitor you for any immediate reactions to the medication. It is important to stay for the entire observation period as directed by your healthcare team.

Missed Appointments

For the treatment to be effective, it is important to follow the scheduled timeline. If you are unable to attend an infusion appointment, notify your healthcare provider immediately to arrange a new time for your dose.

Question 8

Is Renflexis safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

Research regarding the use of Renflexis during pregnancy is limited. As a monoclonal antibody, Renflexis can cross the placenta, especially during the third trimester. This may lead to the medication being present in the newborn's system at birth, which could potentially affect the infant's immune response.

If Renflexis is used during pregnancy, it is important for the healthcare team to be aware. Infants exposed to the drug in utero may need a modified vaccination schedule. Specifically, live vaccines are generally not recommended for these infants for at least six months after birth due to the potential risk of infection.

Breastfeeding

Infliximab products have been detected in human breast milk at low concentrations. While the medication is likely broken down in the infant's digestive tract, which may limit systemic absorption, the full impact on a nursing child is not completely understood.

Individuals who are breastfeeding or planning to breastfeed should consult with their doctor to evaluate the necessity of the treatment and any potential risks to the infant.

Question 9

What forms and strengths does Renflexis come in?

Accepted Answer

Renflexis is supplied in the following form:

Lyophilized powder for injection: This is a sterile, white, preservative-free powder provided in a single-dose vial.

This medication is not for self-administration. A healthcare provider must reconstitute the powder with a liquid and then further dilute it before it is administered. The final solution is given through a needle into a vein, which is called an intravenous (IV) infusion.

Question 10

What is the FDA approval status of Renflexis?

Accepted Answer

FDA Approval and Indications

Renflexis (infliximab-abda) was approved by the FDA in 2017 as a biosimilar to Remicade. It is approved for the treatment of several chronic inflammatory conditions in adults and, in some cases, children. These include:

Crohn’s disease (adults and children 6 years and older)
Ulcerative colitis (adults and children 6 years and older)
Rheumatoid arthritis (in combination with methotrexate)
Ankylosing spondylitis
Psoriatic arthritis
Plaque psoriasis

Boxed Warning

The FDA requires a boxed warning for Renflexis due to the risk of serious infections and malignancy. Patients treated with this medication are at increased risk for developing serious infections that may lead to hospitalization or death, including tuberculosis (TB), bacterial sepsis, and invasive fungal infections. Patients should be tested for latent TB before starting treatment and monitored during therapy.

Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers. Specifically, cases of hepatosplenic T-cell lymphoma have occurred, primarily in adolescent and young adult males with inflammatory bowel disease treated with these products and other immunosuppressants.

Regulatory Classification

As a biosimilar, Renflexis is highly similar to its reference product, Remicade, with no clinically meaningful differences in safety, purity, or potency. It is administered via intravenous infusion by a healthcare professional in a clinical setting.

Question 11

What should I know about Renflexis and cost?

Accepted Answer

Factors Affecting Price

Renflexis is a biosimilar medication, which is designed to be a more cost-effective alternative to the original biological product, Remicade. The total cost of treatment is influenced by several variables:

Body Weight: The dosage is calculated based on kilograms of body weight, meaning the amount of medication needed—and the subsequent cost—will differ for each person.
Infusion Setting: Because this medication must be administered by a healthcare professional through an intravenous (IV) line, costs include not only the drug itself but also facility fees and professional administration charges. Prices may vary between a doctor's office, an independent infusion center, or a hospital setting.
Frequency of Doses: After the initial starting doses, maintenance infusions are typically required every six to eight weeks, which contributes to the long-term cost of therapy.

Insurance Coverage

Most private insurance plans, as well as Medicare and Medicaid, provide coverage for Renflexis. However, many insurers require prior authorization before they will approve payment. Some insurance companies may also have a preferred list of biosimilars, requiring patients to use a specific brand of infliximab to receive the highest level of coverage.

Financial Assistance Programs

For patients who are concerned about out-of-pocket expenses, financial assistance may be available. The manufacturer often provides co-pay assistance programs for patients with commercial insurance to help lower the cost of the medication. Additionally, patient assistance programs may be available for individuals who are uninsured or meet specific financial need criteria.

Renflexis

📋Overview

How It Works

Uses

Active Ingredients

Common Side Effects

Warnings & Precautions

Dosage

Pregnancy & Breastfeeding

Frequently Asked Questions

📚References

Found an Error?

Find Discounts for Renflexis

Hospitals.net Disclosure